Mazdutide

1.Overview

Mazdutide (also known as IBI362) represents a new generation of incretin-based therapeutics. It is a synthetic peptide designed to act as a dual agonist for the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). This dual-action approach is intended to provide a more comprehensive metabolic effect than traditional GLP-1 receptor monotherapies.

In 2025, the agent received its first regulatory approvals in China for the long-term management of body weight in adults with obesity or overweight, as well as for glycemic control in adults with type 2 diabetes. The development of this molecule reflects a strategic shift toward multi-receptor agonists in the treatment of metabolic syndrome.

2.Mechanism of Action

The mechanism of mazdutide is rooted in the 'dual metabolic engine' theory. GLP-1R activation is well-established for its role in stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying, which collectively reduce caloric intake and improve glycemic control.

By adding GCGR agonism, mazdutide aims to increase energy expenditure and promote fat oxidation. While glucagon typically increases blood glucose, the concurrent GLP-1R activation is thought to balance this effect, allowing for weight loss and metabolic improvement without the hyperglycemia that would otherwise be associated with glucagon receptor activation alone.

3.Why Researchers Study It

Current research interest is heavily focused on the long-term metabolic and cardiovascular outcomes of dual-receptor agonism. Investigators are exploring how the balance between GLP-1 and glucagon signaling can be optimized to maximize weight loss while maintaining a favorable safety profile.

Emerging areas of interest include the potential for mazdutide to mitigate diabetes-associated cognitive dysfunction and its efficacy in diverse patient populations. Researchers are also investigating the immunogenicity of the peptide, specifically the development of anti-drug antibodies (ADAs) and their potential impact on long-term therapeutic efficacy.

4.Pharmacology & Molecular Identity

Mazdutide is a long-acting peptide administered once weekly. Its molecular structure is engineered to provide stability and sustained receptor activation. Pharmacokinetically, it is designed to mimic the physiological effects of endogenous incretins while providing a more potent and durable metabolic response.

It is important to distinguish between the established clinical effects—such as significant weight loss and HbA1c reduction—and the theoretical mechanisms of its dual-receptor action. While the synergistic effect on energy expenditure is a primary research hypothesis, the exact contribution of GCGR agonism to human weight loss compared to GLP-1R monotherapy remains a subject of ongoing scientific investigation.

5.Human Research Evidence

Human evidence for mazdutide is primarily derived from clinical trials conducted in China. Phase 2 and Phase 3 trials have consistently shown that mazdutide leads to significant, dose-dependent weight loss and improvements in glycemic markers in patients with obesity and type 2 diabetes.

In comparative studies, mazdutide has demonstrated superiority over certain GLP-1 receptor agonists (such as dulaglutide) in both weight reduction and HbA1c lowering. Clinical data also indicate that the drug is generally well-tolerated, with gastrointestinal side effects being the most frequently reported adverse events.

6.Preclinical Research

Preclinical research has been instrumental in establishing the dual-agonist profile of mazdutide. Animal models have demonstrated that the combination of GLP-1R and GCGR activation leads to greater weight loss and improved metabolic parameters compared to single-receptor activation.

Studies have also explored the potential for these dual agonists to improve synaptic plasticity and mitigate metabolic-associated cognitive decline, though these findings are largely confined to preclinical models and require further validation in human clinical settings.

7.Safety & Research Limitations

The safety profile of mazdutide is characterized by gastrointestinal events, such as nausea and vomiting, which are common among incretin-based therapies. Clinical trials have also observed transient increases in heart rate, though current data have not indicated an increased risk of major adverse cardiovascular events.

Limitations in the current evidence include the relatively short duration of some studies and the concentration of data within specific demographic populations. Additionally, the development of anti-drug antibodies (ADAs) has been noted in some participants, and the long-term clinical significance of these antibodies remains to be fully elucidated.

8.Evidence Quality & Research Gaps

Significant research gaps remain regarding the long-term cardiovascular and neurocognitive effects of dual GLP-1R/GCGR agonism. While initial data are promising, large-scale, long-term studies are needed to confirm the durability of weight loss and the safety of sustained glucagon receptor activation.

Furthermore, there is a need for more diverse clinical trial populations to determine if the efficacy and safety profiles observed in current studies are generalizable to broader global populations. The impact of ADAs on long-term efficacy also warrants further investigation.

9.Frequently Asked Questions

10.References

1. 1.Savas M, Kuckuck S, Boon MR, van Rossum EFC. Beyond weight loss: multisystem benefits of obesity medications. The lancet. Diabetes & endocrinology. 2026 Aug. DOI: 10.1016/S2213-8587(26)00100-2.PMID: 42208956
2. 2.Ji L, Jiang H, Bi Y, Li H, Tian J. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. The New England journal of medicine. 2025 Jun 12. DOI: 10.1056/NEJMoa2411528.PMID: 40421736
3. 3.Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M. Emerging pharmacotherapies for obesity: A systematic review. Pharmacological reviews. 2025 Jan. DOI: 10.1124/pharmrev.123.001045.PMID: 39952695
4. 4.Shirley M. Mazdutide: First Approval. Drugs. 2025 Dec. DOI: 10.1007/s40265-025-02249-y.PMID: 41028652
5. 5.Son JW, le Roux CW, Blüher M, Nauck MA, Lim S. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. Endocrine reviews. 2026 Mar 11. DOI: 10.1210/endrev/bnaf036.PMID: 41054801
6. 6.Xie Z, Zheng G, Liang Z, Li M, Deng W. Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism: clinical and experimental. 2024 Dec. DOI: 10.1016/j.metabol.2024.156038.PMID: 39305981
7. 7.Nong K, Shi Q, Xie X, Wang Y, Agarwal A. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. BMJ (Clinical research ed.). 2026 Jul 8. DOI: 10.1136/bmj-2026-372161.PMID: 42419792
8. 8.Zhang B, Cheng Z, Chen J, Zhang X, Liu D. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes care. 2024 Jan 1. DOI: 10.2337/dc23-1287.PMID: 37943529
9. 9.Guo L, Zhang B, Xue X, Zhang X, Cai H. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026 Apr. DOI: 10.1038/s41586-025-10031-z.PMID: 41407860
10. 10.Ji L, Gao L, Jiang H, Yang J, Yu L. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinicalMedicine. 2022 Dec. DOI: 10.1016/j.eclinm.2022.101691.PMID: 36247927